UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.uams.edu/2022/08/24/uams-receives-3-4-million-to-study-radiation-injuries-caused-by-nuclear-accidents-and-bioterrorism/
Research Institution
University of Arkansas for Medical Sciences
Short Title
UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

$6.9M NIAID Award to Fund Design, Testing of Hepatitis C Vaccine

Seeking Answers to Optimizing Influenza Vaccines in Older Adults Through New Study

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://today.uconn.edu/2022/08/seeking-answers-to-optimizing-influenza-vaccines-in-older-adults-through-new-study/
Research Institution
University of Connecticut
Short Title
Seeking Answers to Optimizing Influenza Vaccines in Older Adults Through New Study
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

More Effective TB Vaccine Goal of Lovell’s Research

Cellular Waste May Supercharge Immune Cell Function

New Method Detects Gut Microbes That Activate Immune Cells

Buck Scientists Highlight New Perspective in How Immunity is Fine-Tuned Through Mechanics

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.buckinstitute.org/news/buck-scientists-highlight-new-perspective-in-how-immunity-is-fine-tuned-through-mechanics/
Research Institution
Buck Institute for Research on Aging
Short Title
Buck Scientists Highlight New Perspective in How Immunity is Fine-Tuned Through Mechanics
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

ACTG Announces Launch Of ACTIV-2d, A Global Phase 3 Trial of The Novel Investigational COVID-19 Oral Antiviral Agent S‑217622

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://actgnetwork.org/2022/08/15/actg-announces-launch-of-activ-2d-a-global-phase-3-trial-of-the-novel-investigational-covid-19-oral-antiviral-agent-s%e2%80%91217622/
Research Institution
ACTG
Short Title
ACTG Announces Launch Of ACTIV-2d, A Global Phase 3 Trial of The Novel Investigational COVID-19 Oral Antiviral Agent S‑217622

Collaborating with the NIH Center for Human Immunology, Inflammation, and Autoimmunity

Collaborative studies aim to leverage the high-dimensional technologies and expertise available in the CHI to enable systems-level characterization of immune phenotypes.  These collaborations can integrate several of the platforms at the CHI, with substantial support from study design to computational analysis. This work will be done in the context of a collaboration with intramural principal investigator(s) (PI), for which we welcome proposals from any NIH institute on any topic involving human samples. 

Epidemiology in the Division of Intramural Research Publications

Subscribe to